The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Head Neck. 2010 Dec;32(12):1597-604. doi: 10.1002/hed.21368.
The aim of this study was to confirm the efficacy of temoporfin (Foscan)-mediated photodynamic therapy (PDT) in patients with end-stage head and neck squamous cell carcinoma (HNSCC).
Thirty-nine patients with recurring HNSCC lesions ≤10 mm in depth were injected with temoporfin, followed by illumination of the tumor surface.
Of 39 treated patients, 19 achieved complete response, 2 partial response, 5 stable disease, 5 had progressive disease, and 8 patients were nonevaluable. Thus, in the per-protocol analysis, the response rate was 68%. Of the treated patients 54% had a response. Median survival was significantly longer for responders (37 months) than for nonresponders (7.4 months). Nine patients were alive at 3.7 to 6.5 years (median, 4.8 years) post-treatment, 7 free of disease. No major toxicities were observed.
Patients with advanced HNSCC with lesions ≤10 mm in depth, who have exhausted other treatment options, can achieve significant local control and survival benefit from temoporfin-mediated PDT.
本研究旨在证实替莫泊芬（Photofrin）介导的光动力疗法（PDT）在晚期头颈部鳞状细胞癌（HNSCC）患者中的疗效。
39 例深度≤10mm 的复发性 HNSCC 病变患者接受替莫泊芬注射，然后对肿瘤表面进行光照。
39 例治疗患者中，19 例完全缓解，2 例部分缓解，5 例疾病稳定，5 例疾病进展，8 例无法评估。因此，在符合方案分析中，缓解率为 68%。在治疗患者中，54%有反应。应答者的中位生存期明显长于无应答者（37 个月与 7.4 个月）。9 例患者在治疗后 3.7 至 6.5 年（中位 4.8 年）时存活，7 例无疾病。未观察到严重毒性。
对于深度≤10mm 的晚期 HNSCC 患者，已用尽其他治疗选择的患者，可从替莫泊芬介导的 PDT 中获得显著的局部控制和生存获益。
